Figure S4. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

• DOI: 10.1158/1078-0432.22477061.v1
• Publication Date: 2023-04-01T14:06:14Z
• Authors: Valeria Merz; Camilla Zecchetto; Raffaela Santoro; Francesca Simionato; Fabio Sabbadini; Domenico Mangiameli; Geny Piro; Alessandro Cavaliere; Michela Deiana; Maria Teresa Valenti; Diana Bazan; Vita Fedele; Sara Lonardi; Davide Melisi
• Keywords: Refractory (planetary science); Interleukin 8

<p>Kaplan-Meier curves of progression-free survival stratifying patients in the discovery cohort for a significant cut-off value eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).</p>